Blacksmith Medicines (formerly known as Forge Therapeutics) is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins Blacksmith has developed a fundamentally new approach for the discovery of metalloprotein inhibitors by focusing first on the metal in the enzyme active site. Using bio-inorganic and medicinal chemistry principles, full-length inhibitors are developed using a novel fragment growth strategy incorporating computational and structural biology.